William Blair reduced their Q1 2025 earnings per share (EPS) estimates for Sapiens International in a report released on Tuesday, February 18th. William Blair analyst D. Becker now anticipates that ...

William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for Booz Allen Hamilton Holding (NYSE:BAH) ...

William Blair downgrades Booz Allen, CACI International, Leidos, Parsons and General Dynamics on the heightened risk of ...

William Blair analyst Brian Drab maintained a Buy rating on Novanta (NOVT – Research Report) today. The company’s shares closed today at ...

William Blair downgraded Booz Allen (BAH) to Market Perform from Outperform.Discover the Best Stocks and Maximize Your Portfolio: See what ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

The U.S. Department of Defense has launched a massive review of consulting services contracts, with an eye toward making cuts ...

Pediatrix Medical reported Q4 revenue of $502.36 million, surpassing estimates, with adjusted EPS of $0.51. The company ...

Read about the Senate confirmation of Kelly Loeffler, a former senator from Georgia and businesswoman, as head of the Small ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...